Stemline Therapeutics (NASDAQ:STML) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Friday.

Several other analysts have also recently weighed in on STML. HC Wainwright set a $38.00 price target on Stemline Therapeutics and gave the company a “buy” rating in a report on Friday, August 10th. ValuEngine raised Stemline Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, August 14th. Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 16th. Wedbush reaffirmed an “outperform” rating and issued a $22.00 price target on shares of Stemline Therapeutics in a report on Monday, November 12th. Finally, Roth Capital set a $33.00 price target on Stemline Therapeutics and gave the company a “buy” rating in a report on Wednesday. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $31.00.

Shares of STML opened at $11.39 on Friday. Stemline Therapeutics has a 52-week low of $11.08 and a 52-week high of $20.55.

Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.06). As a group, equities analysts predict that Stemline Therapeutics will post -2.81 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the business. BlueMountain Capital Management LLC purchased a new stake in shares of Stemline Therapeutics in the 2nd quarter valued at about $137,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Stemline Therapeutics in the 2nd quarter valued at about $166,000. MetLife Investment Advisors LLC raised its holdings in shares of Stemline Therapeutics by 54.6% in the 3rd quarter. MetLife Investment Advisors LLC now owns 18,474 shares of the biopharmaceutical company’s stock valued at $307,000 after acquiring an additional 6,527 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Stemline Therapeutics by 97.8% in the 2nd quarter. Bank of America Corp DE now owns 20,548 shares of the biopharmaceutical company’s stock valued at $329,000 after acquiring an additional 10,159 shares in the last quarter. Finally, Algert Global LLC bought a new position in shares of Stemline Therapeutics during the 2nd quarter valued at about $344,000. 67.03% of the stock is currently owned by hedge funds and other institutional investors.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Featured Article: Return on Investment (ROI) Defined, Explained

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.